Blood cancers, High grade lymphoma, Hodgkin lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Open
Phase 2
This trial is looking at a new drug called MK-3475A for lymphoma that has come back or is getting worse despite treatment.
It is for people who have one of the following types of lymphoma:
the most common type of Hodgkin lymphoma called classical Hodgkin lymphoma
primary mediastinal large B-cell lymphoma
Recruitment start: 6 December 2024
Recruitment end: 30 September 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Graham Collins
Merck Sharp & Dohme Ltd
Last reviewed: 10 March 2025
CRUK internal database number: 20009
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
